Invst Mgrs Srs Trust II AXS Short Innovation Daily ETF (SARK): Head and shoulders top will form

Play Episode

4min

Proactive - Interviews for investors

Mosman Oil and Gas CEO on Vecta Project; drilling set to start in May

Mosman Oil and Gas Ltd (AIM:MSMN) CEO Andy Carroll talked with Proactive's Stephen Gunnion about the latest developments at the Vecta Helium Project in Colorado. Carroll confirmed that drilling is scheduled to begin by mid-May, with rig mobilisation underway and each of the five wells expected to take just two days to drill. Testing will follow before the rig moves to the next location, and a series of drilling updates will begin in approximately four weeks. “It’s the first time we’ve had a specific schedule with Vecta,” Carroll noted, emphasising the significance of this milestone for the company. He said each prospect within the five-well program has its own exploration risk profile, but collectively, the program boosts overall success probability. Carroll also discussed encouraging signs from nearby operations, such as the Blue Star and Helium One joint venture, though highlighted variability in helium concentrations across different wells. Mosman is also progressing other projects, including seismic activity at Coyote Wash and Sagebrush. Carroll said early results are promising, and meetings are ongoing with technical consultants and local stakeholders, including the Ute Mountain Ute Tribe. For more updates from Mosman Oil and Gas Ltd and other interviews, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss a future update. #MosmanOilAndGas #HeliumExploration #VectaProject #ColoradoDrilling #OilAndGasUpdates #EnergySector #HeliumInvestment #SeismicExploration #CoyoteWash #SagebrushProject #ProactiveInvestors #EnergyNews #ResourceSector

Proactive - Interviews for investors

ATOME signs milestone EPC deal with Casale for Villeta project

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive about a landmark milestone for the company’s Villeta green fertiliser project in Paraguay. The company has signed its first definitive engineering, procurement and construction (EPC) agreement with Swiss firm Casale S.A. Mussat explained that this agreement marks the world’s first large-scale green hydrogen fertiliser project to reach the EPC stage, underlining its global relevance. “It’s significant for us as a company because we’ve announced that we had been working on the front-end engineering and design for more than two years now,” Mussat said, noting the long-term collaboration with Casale. He highlighted Casale’s industry-leading expertise, describing the firm as the oldest ammonia licensor globally, with the ability to deliver complex, full-chain fertiliser projects. According to Mussat, the partnership serves as a strategic blueprint for Casale’s future growth. Looking ahead, ATOME aims to reach a final investment decision on the Villeta project by the end of the first half of the year. The company is working to finalise offtake agreements and complete financial documentation for both debt and equity funding. This includes a $115 million equity commitment from Hy24, with further syndication in progress. For more updates on green hydrogen and clean energy developments, visit Proactive’s YouTube channel. Like this video, subscribe, and turn on notifications to stay informed. #ATOMEPLC #GreenHydrogen #EPCContract #FertilizerProject #Casale #SustainableEnergy #CleanTech #HydrogenEconomy #ParaguayProjects #Yara #Hy24

Proactive - Interviews for investors

Ananda Pharma adds former GW Pharmaceuticals executive as strategic advisor, advances MRX1

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors

Proactive - Interviews for investors

Ananda Develops U.S. presence as lead drug advances to Phase 1 clinical study

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Followers	53
Posts	2971
Boards Moderated	0
Alias Born	10/02/2014

Volume:	168,312
Day Range:	56.87 - 58.0693
Bid:	57.00
Ask:	57.78
Last Trade Time:	7:58:21 PM EDT
Total Trades:	1,667

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SARK Detailed Quote

Recent SARK News

More SARK News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent SARK News

Go Ad-Free